Diagnosisy: Anti-thrombotic therapy in patients with atherosclerosis at stroke and above the heart

Recently, the leading journal of neurology, The Journal of Neurology, published a research article aimed at comparing oral anticoagulants and antiplatelet drugs in patients with aortic arch or carotid arteryintracranial arteryand atherosclerosis plaque, collectively known as cardiac atherosclerosisresearchers searched the PubMed and Scopus databases and, as of August 28, 2019, identified randomized trials of oral anticoagulants and anti-platepines in patients with atherosclerosis in stroke and heart aboveThe researchers used the terms 'anticoagulants or anticoagulants' and 'antiplatelets or aspirin' and 'randomized controlled trials or RCT', as well as 'stroke or cerebral ischemia' and 'aortic or cervical or cervical atetries or intracranial or atherosclerosis or stenosis or atestens of the ate.' The researchers assessed four outcomes: repeated ischemic stroke, major ischemic events or deaths, significant bleeding, and intracranial bleedingThe researchers used a meta-analysis to evaluate the therapeutic effect (relative risk (RR) and 95% confidence interval (CI) using a randomeffect modelof the 1117 literatureidentified in the literature search, the meta-analysis eventually included the results of 10 randomized controlled trials involving 6,068 patients with stroke/TIA combined heart atherosclerosisThe incidence of recurrent ischemic stroke in patients receiving anticoagulant drugs was 2.94 per 100 per year, compared to 3.30 persons/100 per year in the antiplatelet drug group (SJRR estimated at 0.91; 95% CI was 0.70-1.18, I2-26 per year)The main local ischemia event or mortality rate in patients given anticoagulant therapy was 4.39 per 100 patients per year, while the number of patients given antiplatelet was 4.32 (RR was 1.03; 95% CI was 0.79-1.35; I2 was 54.5%)The main bleeding rate was 2.88 per 100 per year in patients given anticoagulant treatment, compared to 0.82 (RR 3.21; 95% CI was 1.96-5.24; I2-46%)this systematic evaluation and meta-analysis showed that patients with anticoagulant and above-cardiaat atherosclerosis had no risk of recurrence of ischemic stroke compared to antiplatelet therapy, while the risk of haemorrhage increased